Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients Targeted Oncology 1:07 8 years ago 383 Скачать Далее
Managing cardiovascular risks associated with lifelong TKI therapy in CML VJHemOnc – Video Journal of Hematology & HemOnc 1:42 1 year ago 118 Скачать Далее
Four Approved Frontline Treatments Benefit Patients with Chronic Myeloid Leukemia Targeted Oncology 0:52 5 years ago 190 Скачать Далее
What impact do side effects have on elderly chronic myeloid leukemia (CML) patients? VJHemOnc – Video Journal of Hematology & HemOnc 4:28 7 years ago 3 321 Скачать Далее
Fourth generation TKIs for CML: asciminib VJHemOnc – Video Journal of Hematology & HemOnc 1:32 5 years ago 1 195 Скачать Далее
Asciminib has the potential to succeed where other TKIs have failed in CML VJHemOnc – Video Journal of Hematology & HemOnc 0:58 6 years ago 533 Скачать Далее
Unmet Needs Researchers are Investigating in Chronic Myeloid Leukemia Targeted Oncology 1:04 4 years ago 233 Скачать Далее
Safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients VJHemOnc – Video Journal of Hematology & HemOnc 1:35 7 years ago 373 Скачать Далее
Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial VJHemOnc – Video Journal of Hematology & HemOnc 1:40 7 years ago 452 Скачать Далее
